CD276 as a Candidate Target for Immunotherapy in Medullary Thyroid Cancer.
Kinga Hińcza-NowakArtur KowalikAgnieszka WalczykIwona PałygaDanuta Gąsior-PerczakAgnieszka PłusaJanusz KopczyńskiMagdalena ChrapekStanisław GóźdźAldona KowalskaPublished in: International journal of molecular sciences (2023)
Medullary thyroid cancer (MTC) is a rare malignancy, and the treatment of metastatic MTC is challenging. In previous work, immune profiling (RNA-Seq) of MTC identified CD276 as a potential target for immunotherapy. CD276 expression was 3-fold higher in MTC cells than in normal tissues. Paraffin blocks from patients with MTC were analyzed by immunohistochemistry to confirm the results of RNA-Seq. Serial sections were incubated with anti-CD276 antibody, and scored according to staining intensity and the percentage of immunoreactive cells. The results showed that CD276 expression was higher in MTC tissues than in controls. A lower percentage of immunoreactive cells correlated with the absence of lateral node metastasis, lower levels of calcitonin after surgery, no additional treatments, and remission. There were statistically significant associations of intensity of immunostaining and percentage of CD276 immunoreactive cells with clinical factors and the course of the disease. These results suggest that targeting this immune checkpoint molecule CD276 could be a promising strategy for the treatment of MTC.
Keyphrases
- rna seq
- induced apoptosis
- single cell
- cell cycle arrest
- nk cells
- poor prognosis
- gene expression
- small cell lung cancer
- squamous cell carcinoma
- cell proliferation
- systemic lupus erythematosus
- rheumatoid arthritis
- high intensity
- climate change
- combination therapy
- binding protein
- smoking cessation
- disease activity
- human health